Search
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalTyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth.
Polyvalent antigen-KLH conjugate vaccine
go.drugbank.com/drugs/DB17565InvestigationalIt is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab). … Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant
Brifentanil
go.drugbank.com/drugs/DB09172ExperimentalIllicitBrifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.
RDP58
go.drugbank.com/drugs/DB06566ExperimentalRDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines.
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular deg...
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Oxabolone cipionate
go.drugbank.com/drugs/DB13185ExperimentalIt is considered as a performance enhancing drug thus is prohibited from use in sports.
ABX-PTH
go.drugbank.com/drugs/DB05883ExperimentalABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.
MLN2222
go.drugbank.com/drugs/DB06503ExperimentalMLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.